<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FOSINOPRIL</span><br/>(fos-in'o-pril)<br/><span class="topboxtradename">Monopril<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme (ace) inhibitor</span>; <span class="classification">antihypertensive agent</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Lowers BP by interrupting conversion sequences initiated by renin that lead to formation of angiotensin II, a potent vasoconstrictor.
         Inhibition of ACE also leads to decreased circulating aldosterone, a secretory response to angiotensin II stimulation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers blood pressure and reduces peripheral arterial resistance (afterload) and improves cardiac output as well as activity
         tolerance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension, CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fosinopril or any other ACE inhibitor; pregnancy [category C (first trimester), category D (second or
         third trimesters)], lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function, hyperkalemia, or surgery and anesthesia. Safety in children is not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, CHF</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 540 mg once/d (max: 80 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue diuretics 23 d before initiation of therapy if possible. If diuretics cannot be discontinued, start initial
            dose <img src="../images/special/lesserorequal.gif"/>10 mg.
         </li>
<li>Store at 15°30° C (59°86° F) and protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Hypotension. <span class="typehead">CNS:</span> Headache, fatigue, dizziness. <span class="typehead">Endocrine:</span> Hyperkalemia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Urogenital:</span> Proteinuria. <span class="typehead">Respiratory:</span> Cough. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">nsaid</span>s may decrease antihypertensive effects of fosinopril. <span class="classification">potassium supplements</span>, <span class="classification">potassium-sparing diuretics</span> increase risk of hyperkalemia. ACE inhibitors may increase <b>lithium</b> levels and toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; converted to its active form, fosinoprilat, in the liver. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Approximately 90% protein bound; crosses placenta. <span class="typehead">Metabolism:</span> Hydrolyzed by intestinal and hepatic esterases to its active form, fosinoprilat. <span class="typehead">Elimination:</span> 44% excreted in urine, 46% in feces. <span class="typehead">Half-Life:</span> 34 h (fosinoprilat). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP at the time of peak effectiveness, 26 h after dosing and at the end of the dosing interval just before next
            dose.
         </li>
<li>Report diminished antihypertensive effect toward the end of the dosing interval. An inadequate trough response may be an indication
            for dividing the daily dose.
         </li>
<li>Monitor for first-dose hypotension, especially in salt- or volume-depleted patients.</li>
<li>Lab tests: Obtain BUN and serum creatinine periodically. Increases may necessitate dose reduction or discontinuation of the
            drug. Monitor serum potassium.
         </li>
<li>Observe for S&amp;S of hyperkalemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue fosinopril and report to physician any of the following: S&amp;S of angioedema (e.g., swelling of face or extremities,
            difficulty breathing or swallowing); syncope; chronic, nonproductive cough.
         </li>
<li>Maintain adequate fluid intake and avoid potassium supplements or salt substitutes unless specifically prescribed by the physician.</li>
<li>Report vomiting or diarrhea to physician immediately.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>